Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline — Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1...
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Combined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation...
Recent Comments